INFI
Income statement / Annual
Last year (2022), Infinity Pharmaceuticals, Inc.'s total revenue was $2.59 M,
an increase of 39.56% from the previous year.
In 2022, Infinity Pharmaceuticals, Inc.'s net income was -$43.26 M.
See Infinity Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$2.59 M
|
$1.86 M
|
$1.72 M
|
$3.05 M
|
$22.15 M
|
$6.00 M
|
$18.72 M
|
$109.07 M
|
$165.00 M
|
$0.00
|
| Cost of Revenue |
$1.56 M |
$1.12 M |
$1.04 M |
$7.31 M |
$69,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$1.03 M |
$738,000.00 |
$682,000.00 |
-$4.26 M |
$22.08 M |
$6.00 M |
$18.72 M |
$109.07 M |
$165.00 M |
$0.00 |
| Gross Profit Ratio |
0.4 |
0.4 |
0.4 |
-1.4 |
1 |
1 |
1 |
1 |
1 |
0 |
| Research and Development
Expenses |
$32.41 M
|
$31.65 M
|
$26.76 M
|
$27.12 M
|
$19.76 M
|
$20.83 M
|
$119.61 M
|
$199.11 M
|
$143.63 M
|
$99.76 M
|
| General & Administrative
Expenses |
$13.46 M
|
$14.17 M
|
$12.42 M
|
$14.29 M
|
$14.25 M
|
$21.62 M
|
$42.22 M
|
$37.07 M
|
$29.29 M
|
$27.92 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.46 M
|
$14.17 M
|
$12.42 M
|
$14.29 M
|
$14.25 M
|
$21.62 M
|
$42.22 M
|
$37.07 M
|
$29.29 M
|
$27.92 M
|
| Other Expenses |
$1.56 M |
$1.12 M |
$1.04 M |
$7.31 M |
$69,000.00 |
-$6.88 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$45.87 M |
$45.82 M |
$39.18 M |
$41.41 M |
$34.01 M |
$42.45 M |
$161.83 M |
$236.17 M |
$172.92 M |
$127.68 M |
| Cost And Expenses |
$47.44 M |
$46.94 M |
$40.22 M |
$48.71 M |
$34.08 M |
$42.45 M |
$161.83 M |
$236.17 M |
$172.92 M |
$127.68 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$339,000.00 |
$0.00 |
| Interest Expense |
$180,000.00 |
$180,000.00 |
$2.45 M |
$2.56 M |
$93,000.00 |
$1.01 M |
$1.23 M |
$1.37 M |
$9.65 M |
$0.00 |
| Depreciation &
Amortization |
$458,000.00
|
$480,000.00
|
$483,000.00
|
$219,000.00
|
$191,000.00
|
$1.72 M
|
$3.42 M
|
$2.29 M
|
$1.77 M
|
$1.82 M
|
| EBITDA |
-$44.84 M
|
-$44.60 M
|
-$38.01 M
|
-$45.66 M
|
-$11.74 M
|
-$43.33 M
|
-$30.89 M
|
-$127.11 M
|
-$7.58 M
|
-$125.85 M
|
| EBITDA Ratio |
-17.29 |
-24.01 |
-22.11 |
-14.98 |
-0.53 |
-7.22 |
-7.64 |
-1.17 |
-0.05 |
0 |
| Operating Income Ratio
|
-17.29
|
-24.26
|
-22.39
|
-14.98
|
-0.54
|
-6.07
|
-1.65
|
-1.17
|
-0.05
|
0
|
| Total Other
Income/Expenses Net |
$475,000.00
|
-$179,000.00
|
-$2.00 M
|
-$1.45 M
|
$676,000.00
|
-$6.11 M
|
$790,000.00
|
-$933,000.00
|
-$9.31 M
|
$896,000.00
|
| Income Before Tax |
-$44.37 M |
-$45.26 M |
-$40.49 M |
-$47.11 M |
-$11.25 M |
-$42.55 M |
-$30.10 M |
-$128.04 M |
-$17.23 M |
-$126.78 M |
| Income Before Tax Ratio
|
-17.11
|
-24.36
|
-23.56
|
-15.45
|
-0.51
|
-7.09
|
-1.61
|
-1.17
|
-0.1
|
0
|
| Income Tax Expense |
-$1.11 M |
$180,000.00 |
$2.45 M |
-$54,000.00 |
$769,000.00 |
-$720,000.00 |
-$2.19 M |
$335,000.00 |
$183,000.00 |
$0.00 |
| Net Income |
-$43.26 M |
-$45.44 M |
-$42.94 M |
-$47.06 M |
-$11.25 M |
-$41.83 M |
-$30.10 M |
-$128.38 M |
-$17.42 M |
-$126.78 M |
| Net Income Ratio |
-16.68 |
-24.46 |
-24.98 |
-15.43 |
-0.51 |
-6.97 |
-1.61 |
-1.18 |
-0.11 |
0 |
| EPS |
-0.48 |
-0.53 |
-0.72 |
-0.83 |
-0.2 |
-0.83 |
-0.61 |
-2.62 |
-0.36 |
-2.64 |
| EPS Diluted |
-0.48 |
-0.53 |
-0.72 |
-0.83 |
-0.2 |
-0.83 |
-0.61 |
-2.62 |
-0.36 |
-2.64 |
| Weighted Average Shares
Out |
$89.25 M
|
$85.60 M
|
$59.86 M
|
$56.98 M
|
$55.41 M
|
$50.56 M
|
$49.61 M
|
$49.08 M
|
$48.56 M
|
$47.94 M
|
| Weighted Average Shares
Out Diluted |
$89.25 M
|
$85.60 M
|
$59.86 M
|
$56.98 M
|
$55.41 M
|
$50.56 M
|
$49.61 M
|
$49.08 M
|
$48.56 M
|
$47.94 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
